SLXN - Biomotion Sciences Ordinary Shares

SLXN - Biomotion Sciences Ordinary Shares

https://silexion.com

Recent News

Powered by Alpha Vantage

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data - Silexion Therapeutics ( NASDAQ:SLXN )

Benzinga • 3 days, 22 hours ago • score: 0.21

SIL204 reached all primary metastatic sites and reduced tumor burden in the liver, lung and intestine in pancreatic cancer mouse models. Silexion plans Phase 2/3 trials in H1 2026, with regulatory submissions set for late 2025 and early 2026. Up Next: Get 5 Dark Horse Stocks Wall Street Is ...

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference - Silexion Therapeutics ( NASDAQ:SLXN )

Benzinga • 1 week, 6 days ago • score: 0.14

Grand Cayman, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Silexion Therapeutics Corp. SLXN ( "Silexion" or the "Company" ) , a clinical-stage biotechnology company pioneering RNA interference ( RNAi ) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the ...

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

GlobeNewswire • 1 week, 6 days ago • score: 0.14

Grand Cayman, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Silexion Therapeutics Corp. ( NASDAQ: SLXN ) ( "Silexion" or the "Company" ) , a clinical-stage biotechnology company pioneering RNA interference ( RNAi ) therapies for KRAS-driven cancers, today announced that senior management will be ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$63.45

52W Low

$3.11

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.04

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

43.59

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

2.00%

Institutions (25–75% balanced)

6.29%

Shares Outstanding

731,640

Float

0

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-30.78

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.17%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—